ArticleFrontiers in oncology2026
The prognostic significance of CCL2 in oral squamous cell carcinoma: insights from tissue expression and perioperative serum profiling.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to examine the expression patterns of chemokine CCL2 in oral squamous cell carcinoma tissues, adjacent tissues and tumor microenvironment, including the examine of the paraffin block and the examination of the peripheral blood. It seeks to analyze the associations between CCL2 expression and clinical features, pathological characteristics, and prognosis, as well as assess its potential as a prognostic biomarker. Methods: We enrolled 119 patients with OSCC in this study. Immunohistochemistry detected CCL2 protein expression in cancerous and adjacent tissues. We used enzyme-linked immunosorbent assay (ELISA) to quantify serum CCL2 concentrations in patients both pre- and post-surgery. The chi-square test analyzed the correlation between CCL2 expression and clinical characteristics. We applied the paired t-test to compare pre- and post-surgery CCL2 changes. The Kaplan-Meier method evaluated CCL2's impact on overall survival (OS) and disease-free survival (DFS) of patients. Results: Immunohistochemical analysis revealed that CCL2 expression was significantly elevated in OSCC tissues compared to adjacent normal tissues (P < 0.05). High CCL2 expression correlated strongly with advanced T stage (P = 0.002), clinical stage (P = 0.001), and lymph node metastasis (P = 0.001). Survival analysis showed that patients with elevated CCL2 levels in tumor tissues had significantly shorter overall survival (P < 0.001). Serological analysis indicated a significant overall decrease in postoperative serum CCL2 levels (P = 0.002); however, this decrease was not pronounced in patients with advanced stages (T3-4, stage III-IV) or recurrence. A combined analysis revealed that patients with high CCL2 expression in OSCC and increased postoperative serum CCL2 had the poorest disease-free and overall survival (P < 0.05). Conversely, patients with high CCL2 expression in OSCC and decreased postoperative serum CCL2 exhibited the best disease-free and overall survival (P < 0.05). Conclusion: The expression level of chemokine CCL2 in oral squamous cell carcinoma was significantly correlated with strong tumor invasiveness and poor prognosis. Persistently high CCL2 expression after surgery indicated a high risk of recurrence and metastasis, as well as poor prognosis. Dynamic monitoring of serum CCL2 levels is expected to become a biomarker for evaluating surgical efficacy and predicting recurrence risk. The CCL2/CCR2 signaling axis offers a new research direction for treating oral squamous cell carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.